Bosutinib (BOS) vs Imatinib (IM) for Newly Diagnosed Chronic Myeloid Leukemia (CML): Initial Results from the BFORE Trial

BOS is a dual SRC/ABL tyrosine kinase inhibitor approved for adults with Philadelphia chromosome-positive (Ph+) CML resistant or intolerant to prior therapy.

Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Jorge Cortes, Carlo Gambacorti-Passerini, Michael Deininger, Michael Mauro, Charles Chuah, Dong Wook Kim, Laurence Reilly, Alison Jeynes-Ellis, Eric Leip, Nathalie Bardy-Bouxin, Andreas Hochhaus, Tim Br ümmendorf Source Type: research